Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Breast Neoplasms 20Carcinoma, Renal Cell 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 13Neoplasms 11Neuroendocrine Tumors 10Recurrence 8Lung Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Prostatic Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma 5Leukemia, Myeloid, Acute 5Kidney Neoplasms 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Hodgkin Disease 4Head and Neck Neoplasms 4Glioblastoma 4Waldenstrom Macroglobulinemia 3Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3

Interventions

Azacitidine 56Cyclophosphamide 44fludarabine phosphate 42fludarabine 37Decitabine 27venetoclax 26Cytarabine 25Tacrolimus 20Specimen Handling 18Filgrastim 18Busulfan 18Melphalan 17Whole-Body Irradiation 16Mycophenolic Acid 16Antilymphocyte Serum 14Granulocyte Colony-Stimulating Factor 12Clofarabine 12Biopsy 12Peripheral Blood Stem Cell Transplantation 11Injections 11Etoposide 11Methotrexate 10thymoglobulin 9Thiotepa 9Stem Cell Transplantation 9Lenalidomide 9decitabine and cedazuridine drug combination 8aldesleukin 8Sirolimus 8Nivolumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Myelodysplastic Syndromes × Everolimus × Clear all
NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
29 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡